Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: A haplotype assessment

Pharmacogenomics

Volumn 10, Issue 6, 2009, Pages 931-944

  Amstutz, Ursula ^a   Farese, Simone ^a   Aebi, Stefan ^a   Largíadér, Carlo R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

5 Fluorouracil; Capecitabine; Dihydropyrimidine dehydrogenase; Gene polymorphism; Haplotype

Indexed keywords

ADENINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GUANINE; THYMINE;

ADJUVANT THERAPY; ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; DIARRHEA; DISEASE SEVERITY; DNA FLANKING REGION; DRUG DOSE REDUCTION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; DRY SKIN; ENTERITIS; EXON; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL DISEASE; GENE FREQUENCY; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HAIR LOSS; HAND FOOT SYNDROME; HAPLOTYPE; HEMATOLOGIC DISEASE; HUMAN; INFECTION; INTRON; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; MUCOSA INFLAMMATION; NAUSEA; NUCLEIC ACID BASE SUBSTITUTION; PHARMACOGENOMICS; PROGNOSIS; SEQUENCE ANALYSIS; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FLUOROURACIL; GENE FREQUENCY; GENETIC VARIATION; HAPLOTYPES; HUMANS; INTRONS; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; POLYMORPHISM, GENETIC; SEQUENCE ANALYSIS, DNA; SEVERITY OF ILLNESS INDEX; STOMACH NEOPLASMS;

EID: 69049114190     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.28     Document Type: Article

References (28)

1. Ezzeldin H, Diasio RB: Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin. Colorectal Cancer 4, 181-189 (2004).
2. Levy E, Piedbois P, Buyse M et al.: Toxicity of fluorouracil in patients with advanced colorectal cancer: Effect of administration schedule and prognostic factors. J. Clin. Oncol. 16, 3537-3541 (1998).
3. Ezzeldin HH, Diasio RB: Predicting fluorouracil toxicity: can we finally do it? J. Clin. Oncol. 26, 2080-2082 (2008).
4. Soong R, Diasio RB: Advances and challenges in fluoropyrimidine pharmacogenomics and pharmacogenetics. Pharmacogenomics 6, 835-847 (2005).
5. Lim W-T, McLeod HL: Should screening for DPD deficiency be mandatory before 5-FU exposure? Onkologie 27, 531-533 (2004).
6. Morel A, Boisdron-Celle M, Fey L et al.: Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 5, 2895-2904 (2006).
7. Schwab M, Zanger UM, Marx C et al.: Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU toxicity study group. J. Clin. Oncol. 26, 2131-2138 (2008).
8. Pagani F, Baralle FE: Genomic variants in exons and introns: identifying the splicing spoilers. Nat. Rev. Genet. 5, 389-396 (2004).
9. Wang G-S, Cooper TA: Splicing in disease: disruption of the splicing code and the decoding machinery. Nat. Rev. Genet. 8, 749-761 (2007).
10. Horn MP, Mäder-Heinemann G, Andrey-Zürcher G, Largiadèr CR: Mutation screening of the medium-chain acyl-CoA dehydrogenase (MCAD) and the ornithine transcarbamylase (OTC) genes by multiplex PCR. Clin. Chem. Lab. Med. 47, 56-59 (2009).
11. Excoffier L, Laval G, Schneider S: Arlequin ver. 3.0: an integrated software package for population genetics data analysis. Evol. Bioinform. Online 1, 47-50 (2005).
12. Lewontin RC: The interaction of selection and linkage. I. General considerations; heterotic models. Genetics 49, 49-67 (1964).
13. Hill WG: Estimation of linkage disequilibrium in randomly mating populations. Heredity 33, 229-239 (1974).
14. Rousset F: GENEPOP'007: a complete re-implementation of the GENEPOP software for Windows and Linux. Mol. Ecol. Resour. 8, 103-106 (2008).
15. Excoffier L, Estoup A, Cornuet J-M: Gametic phase estimation over large genomic regions using an adaptive window approach. Hum. Genomics 1, 7-19 (2003).
16. Benjamini Y, Hochberg Y: Controlling the false discovery rate - a practical and powerful approach to multiple testing. J. R. Stat. Soc. Ser. B. 57, 289-300 (1995).
17. Seck K, Riemer S, Kates R et al.: Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin. Cancer Res. 11, 5886-5892 (2005).
18. Ezzeldin H, Okamoto Y, Johnson MR, Diasio RB: A high-throughput denaturing high-performance liquid chromatography method for the identification of variant alleles associated with dihydropyrimidine dehydrogenase deficiency. Anal. Biochem. 306, 63-73 (2002).
19. Zuccato E, Buratti E, Stuani C, Baralle FE, Pagani F: An intronic polypyrimidine-rich element downstream of the donor site modulates cystic fibrosis transmembrane conductance regulator exon 9 alternative splicing. J. Biol. Chem. 279, 16980-16988 (2004).
20. Hegde S, Lenox LE, Lariviere A et al.: An intronic sequence mutated in flexed-tail mice regulates splicing of Smad5. Mamm. Genome 18, 852-860 (2007).
21. Estivill X, Bancells C, Ramos C; Consortium BCMA: Geographic distribution and regional origin of 272 cystic fibrosis mutations in European populations. Hum. Mutat. 10, 135-154 (1997).
22. van Kuilenburg ABP, Meinsma R, Zoetekouw L, Gennip AHV: High prevalence of the IVS14+ 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12, 555-558 (2002).
23. Magné N, Etienne-Grimaldi M-C, Cals L et al.: Dihydropyrimidine dehydrogenase activity and the IVS14+1G>A mutation in patients developing 5FU-related toxicity. Br. J. Clin. Pharmacol. 64, 237-240 (2007).
24. Collie-Duguid ES, Johnston SJ, Powrie RH et al.: Cloning and initial characterization of the human DPYD gene promoter. Biochem. Biophys. Res. Commun. 271, 28-35 (2000).
25. Johnson MR, Wang K, Diasio RB: Profound dihydropyrimidine dehydrogenase deficiency resulting from a novel compound heterozygote genotype. Clin. Cancer Res. 8, 768-774 (2002).
26. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB: Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin. Cancer Res. 11, 8699-8705 (2005).
27. Amstutz U, Farese S, Aebi S, Largiadèr CR: Hypermethlyation of the DPYD promoter region is not a major pedictor of severe toxicity in 5-fluorouracil based chemotherapy. J. Exp. Clin. Cancer Res. 27, 54 (2008).
28. Ciccolini J, Mercier C, Evrard A et al.: A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28, 678-685 (2006).